This study analyzes FDA approved novel therapeutic drugs over the past three decades to identify trends in drug development. The study collected and analyzed information on drug attributes, approval types, and targeted diseases for drugs approved between 1991 and 2023. Results show that the FDA has approved 1096 novel drugs, with 79% being new molecular entities (NME) and 21% being biologics. Priority review was granted to 46% of the drugs, and 34% were given orphan status. Breakthrough therapy status was granted for 11% of the drugs, and 7% received accelerated approval. Novartis sponsored the highest number of approved drugs, with 54 in total. Around 22% of the drugs approved were cancer-related, with lung and breast cancer being the top two types. The study concludes that FDA's regulatory incentives could facilitate the pharmaceutical industry in addressing new challenges and bringing innovation in the future. A user-friendly web portal and application is in development to allow user to access updated comprehensive information of novel drugs all in one place.